|
|
|
Hepatitis Clinical Trials, Diagnosis, and Treatment |
|
Thank you for your interest in clinical trials for
Hepatitis.
Please click "Search" to find Hepatitis clinical trials and medical research
studies or read below for information on Hepatitis diagnosis and treatment.
If you receive too many study listings you may enter your zip code to find the
locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 7 studies:
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Subjects - NCT01157104-68502
Conditions: Chronic Hepatitis C Location: Lincoln, NE
- A Network & Dyad HIV Prevention Intervention for IDU's - 1 - NCT00218335-21231
Conditions: HIV - Hepatitis Location: Baltimore, MD
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-02114
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: Boston, MA
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-07102
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: Newark, NJ
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-10021
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: New York, NY
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-14642
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: Rochester, NY
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-21093
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: Lutherville, MD
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-23298
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: Richmond, VA
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-34243
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: Sarasota, FL
- A Phase II Study to Determine the Safety and Efficacy of Interferon-Gamma in Patients With Chronic Hepatitis B - NCT00753467-91105
Conditions: Hepatitis B Location: Pasadena, CA
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02114
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Boston, MA
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02115
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Boston, MA
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-02903
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Providence, RI
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-06106
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Hartford, CT
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-10029
Conditions: Chronic Hepatitis B Virus, Pediatric Location: New York, NY
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-19104
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Philadelphia, PA
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-20010
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Washington, DC
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-21287
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Baltimore, MD
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-22031
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Fairfax, VA
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-28226
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Charlotte, NC
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-32610
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Gainesville, FL
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-77030
Conditions: Chronic Hepatitis B Virus, Pediatric Location: Houston, TX
- A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection - NCT01079806-94143
Conditions: Chronic Hepatitis B Virus, Pediatric Location: San Francisco, CA
- A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection - NCT01091077-02114
Conditions: Hepatitis C Virus - HCV Infection - Chronic HCV - Hepatitis C Location: Boston, MA
- A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation - NCT01074203-55905
Conditions: Hepatitis C Recurrence Location: Rochester, MN
- A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C - NCT00814606-60637
Conditions: Hepatitis C - Hepatitis C Virus Location: Chicago, IL
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-10016
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: New York, NY
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-21093
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Lutherville, MD
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27599
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Chapel Hill, NC
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-27705
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Durham, NC
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32803
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Orlando,, FL
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-32809
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Orlando, FL
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-33136
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Miami, FL
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-46202
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Indianapolis, IN
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-48202
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Detroit, MI
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-53792
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Madison, WI
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-55446
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Plymouth, MN
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-60611
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Chicago, IL
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-63104
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: St. Louis, MO
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70112
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: New Orleans, LA
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-70808
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Baton Rouge, LA
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-75203
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Dallas, TX
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-77030
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Houston, TX
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-78234
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: San Antonio, TX
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-80045
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Aurora, CO
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-85054
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Phoenix, AZ
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-90048
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Los Angeles, CA
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92037
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: La Jolla, CA
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-92801
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Anaheim,, CA
- A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 - NCT01074008-98101
Conditions: Hepatitis C - HCV - Chronic Hepatitis C - Hepatitis C Genotype 1 Location: Seattle, WA
- A Randomized Trial of Vaccine Adherence in Young Injection Drug Users - 1 - NCT00244374-94143
Conditions: Adherence - Community Outreach - HIV Risk Behaviors - Hepatitis A Vaccines - Hepatitis B Vaccines - Hepatitis C - Needle-Exchange Programs - Substance Abuse, Intravenous Location: San Francisco, CA
- A Randomized, Controlled Trial of Fluvastatin Added to Pegylated Interferon and Ribavirin (PI+R) Versus PI+R Alone for Treatment of Chronic Hepatitis C Not Previously Treated - NCT00487318-73104
Conditions: Chronic Hepatitis C Location: OKlahoma City, OK
- A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection - NCT01080222-
Conditions: Chronic Hepatitis C Virus Infection Location: Falls Church, VA
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-01702
Conditions: Chronic Hepatitis C Location: Framingham, MA
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-07102
Conditions: Chronic Hepatitis C Location: Newark, NJ
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-08360
Conditions: Chronic Hepatitis C Location: Vineland, NJ
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-10016
Conditions: Chronic Hepatitis C Location: New York, NY
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-12601
Conditions: Chronic Hepatitis C Location: Poughkeepsie, NY
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-28801
Conditions: Chronic Hepatitis C Location: Asheville, NC
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-29204
Conditions: Chronic Hepatitis C Location: Columbia, SC
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-30060
Conditions: Chronic Hepatitis C Location: Marietta, GA
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-32803
Conditions: Chronic Hepatitis C Location: Orlando, FL
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-34243
Conditions: Chronic Hepatitis C Location: Sarasota, FL
- A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C - NCT01087944-78215
Conditions: Chronic Hepatitis C Location: San Antonio, TX
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-03756
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Lebanon, NH
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-10032
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: New York, NY
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-19141
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Philadelphia, PA
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20010
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Washington, DC
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-20707
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Laurel, MD
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-23206
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Newport News, VA
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-30060
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Mareitta, GA
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-32803
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Orlando, FL
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-33319
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Tamarac, FL
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-34243
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Sarasota, FL
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-75246
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Dallas, TX
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92105
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: San Diego, CA
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-92118
Conditions: Chronic Hepatitis C Virus Genotype 1 Location: Coronado, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-02114
Conditions: Hepatitis C, Chronic Location: Boston, MA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-07601
Conditions: Hepatitis C, Chronic Location: Hackensack, NJ
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-08234
Conditions: Hepatitis C, Chronic Location: Egg Harbour Township, NJ
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-10016
Conditions: Hepatitis C, Chronic Location: New York, NY
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-13210
Conditions: Hepatitis C, Chronic Location: Syracuse, NY
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22031
Conditions: Hepatitis C, Chronic Location: Fairfax, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22908
Conditions: Hepatitis C, Chronic Location: Charlottesville, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-23249
Conditions: Hepatitis C, Chronic Location: Richmond, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27103
Conditions: Hepatitis C, Chronic Location: Winston-salem, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27599
Conditions: Hepatitis C, Chronic Location: Chapel Hill, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-28801
Conditions: Hepatitis C, Chronic Location: Asheville, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30060
Conditions: Hepatitis C, Chronic Location: Marietta, GA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30308
Conditions: Hepatitis C, Chronic Location: Atlanta, GA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32256
Conditions: Hepatitis C, Chronic Location: Jacksonville, FL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32803
Conditions: Hepatitis C, Chronic Location: Orlando, FL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-35294
Conditions: Hepatitis C, Chronic Location: Birmingham, AL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-37660
Conditions: Hepatitis C, Chronic Location: Kingsport, TN
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-38801
Conditions: Hepatitis C, Chronic Location: Tupelo, MS
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63104
Conditions: Hepatitis C, Chronic Location: St Louis, MO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63110
Conditions: Hepatitis C, Chronic Location: St Louis, MO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70520
Conditions: Hepatitis C, Chronic Location: Opelousas, LA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70890
Conditions: Hepatitis C, Chronic Location: Baton Rouge, LA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-73112
Conditions: Hepatitis C, Chronic Location: Oklahoma City, OK
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-78234
Conditions: Hepatitis C, Chronic Location: Fort Sam Houston, TX
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-80045
Conditions: Hepatitis C, Chronic Location: Aurora, CO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-84132
Conditions: Hepatitis C, Chronic Location: Salt Lake City, UT
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-87131
Conditions: Hepatitis C, Chronic Location: Albuquerque, NM
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90048
Conditions: Hepatitis C, Chronic Location: Los Angeles, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90057
Conditions: Hepatitis C, Chronic Location: Los Angeles, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90505
Conditions: Hepatitis C, Chronic Location: Torrance, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90822
Conditions: Hepatitis C, Chronic Location: Long Beach, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92037
Conditions: Hepatitis C, Chronic Location: La Jolla, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92103
Conditions: Hepatitis C, Chronic Location: San Diego, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-93534
Conditions: Hepatitis C, Chronic Location: Lancaster, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95816
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95817
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-96813
Conditions: Hepatitis C, Chronic Location: Honolulu, HI
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-97239
Conditions: Hepatitis C, Chronic Location: Portland, OR
- A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both - NCT00962871-94143
Conditions: Hepatitis B, Chronic Location: San Francisco, CA
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02115
Conditions: Hepatitis B, Chronic Location: Boston, MA
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02903
Conditions: Hepatitis B, Chronic Location: Providence, RI
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-06106
Conditions: Hepatitis B, Chronic Location: Hartford, CT
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-10029
Conditions: Hepatitis B, Chronic Location: New York, NY
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-19104
Conditions: Hepatitis B, Chronic Location: Philadelphia, PA
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-21287
Conditions: Hepatitis B, Chronic Location: Baltimore, MD
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-32610
Conditions: Hepatitis B, Chronic Location: Gainesville, FL
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-75390
Conditions: Hepatitis B, Chronic Location: Dallas, TX
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-94143
Conditions: Hepatitis B, Chronic Location: San Francisco, CA
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Baltimore, MD
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-20892
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Bethesda, MD
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-21205
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Baltimore, MD
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-02905
Conditions: Hepatitis C, Chronic Location: Providence, RI
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-10021
Conditions: Hepatitis C, Chronic Location: New York, NY
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-11030
Conditions: Hepatitis C, Chronic Location: Manhasset, NY
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-21205
Conditions: Hepatitis C, Chronic Location: Baltimore, MD
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-23249
Conditions: Hepatitis C, Chronic Location: Richmond, VA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-27599
Conditions: Hepatitis C, Chronic Location: Chapel Hill, NC
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-37211
Conditions: Hepatitis C, Chronic Location: Nashville, TN
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-78215
Conditions: Hepatitis C, Chronic Location: San Antonio, TX
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-84132
Conditions: Hepatitis C, Chronic Location: Salt Lake City, UT
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-92118
Conditions: Hepatitis C, Chronic Location: Coronado, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-94115
Conditions: Hepatitis C, Chronic Location: San Francisco, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-95817
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-97239
Conditions: Hepatitis C, Chronic Location: Portland, OR
- A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies - NCT00962975-94143
Conditions: Hepatitis B, Chronic Location: San Francisco, CA
- A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-14642
Conditions: Chronic Hepatitis C Infection (HCV) Location: Rochester, NY
- A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-21201
Conditions: Chronic Hepatitis C Infection (HCV) Location: Baltimore, MD
- A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-28203
Conditions: Chronic Hepatitis C Infection (HCV) Location: Charlotte, NC
- A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-70808
Conditions: Chronic Hepatitis C Infection (HCV) Location: Baton Rouge, LA
- A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-78215
Conditions: Chronic Hepatitis C Infection (HCV) Location: San Antonio, TX
- A Study of Vaniprevir (MK7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies - NCT00943761-98103
Conditions: Chronic Hepatitis C Infection (HCV) Location: Seattle, WA
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-01655
Conditions: Hepatitis C Location: Worcester, MA
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-01702
Conditions: Hepatitis C Location: Framingham, MA
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-28304
Conditions: Hepatitis C Location: Fayetteville, NC
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-32256
Conditions: Hepatitis C Location: Jacksonville, FL
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-32803
Conditions: Hepatitis C Location: Orlando, FL
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-33136
Conditions: Hepatitis C Location: Miami, FL
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-33162
Conditions: Hepatitis C Location: Miami, FL
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-10468
Conditions: Hepatitis C Location: Bronx, NY
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-92161
Conditions: Hepatitis C Location: San Diego, CA
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-94304
Conditions: Hepatitis C Location: Palo Alto, CA
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-02905
Conditions: Hepatitis C, Chronic Location: Providence, RI
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-07102
Conditions: Hepatitis C, Chronic Location: Newark, NJ
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-10021
Conditions: Hepatitis C, Chronic Location: New York, NY
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-21093
Conditions: Hepatitis C, Chronic Location: Lutherville, MD
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-23249
Conditions: Hepatitis C, Chronic Location: Richmond, VA
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-29204
Conditions: Hepatitis C, Chronic Location: Columbia, SC
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-30060
Conditions: Hepatitis C, Chronic Location: Marietta, GA
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-32610
Conditions: Hepatitis C, Chronic Location: Gainesville, FL
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-34243
Conditions: Hepatitis C, Chronic Location: Sarasota, FL
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-35294
Conditions: Hepatitis C, Chronic Location: Birmingham, AL
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-37211
Conditions: Hepatitis C, Chronic Location: Nashville, TN
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-60637
Conditions: Hepatitis C, Chronic Location: Chicago, IL
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-64131
Conditions: Hepatitis C, Chronic Location: Kansas City, MO
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-77030
Conditions: Hepatitis C, Chronic Location: Houston, TX
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-78234
Conditions: Hepatitis C, Chronic Location: Fort Sam Houston, TX
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-80045
Conditions: Hepatitis C, Chronic Location: Aurora, CO
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-92037
Conditions: Hepatitis C, Chronic Location: La Jolla, CA
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-92154
Conditions: Hepatitis C, Chronic Location: San Diego, CA
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-94115
Conditions: Hepatitis C, Chronic Location: San Francisco, CA
- An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens - NCT01168856-95817
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95661
Conditions: Hepatitis C Location: Roseville, CA
- Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95825
Conditions: Hepatitis C Location: Sacramento, CA
- Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection - NCT00239733-10021
Conditions: Thrombocytopenia - Hepatitis C - HIV Infections Location: New York, NY
- Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-92103
Conditions: Chronic Hepatitis C Infection Location: San Diego, CA
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-55417
Conditions: Hepatitis C - Alcohol Use Disorders Location: Minneapolis, MN
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-90822
Conditions: Hepatitis C - Alcohol Use Disorders Location: Long Beach, CA
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-97201
Conditions: Hepatitis C - Alcohol Use Disorders Location: Portland, OR
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-07102
Conditions: Hepatitis C Virus - HIV Infections Location: Newark, NJ
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-21287
Conditions: Hepatitis C Virus - HIV Infections Location: Baltimore, MD
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-30308
Conditions: Hepatitis C Virus - HIV Infections Location: Atlanta, GA
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-75204
Conditions: Hepatitis C Virus - HIV Infections Location: Dallas, TX
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-90036
Conditions: Hepatitis C Virus - HIV Infections Location: Los Angeles, CA
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-92663
Conditions: Hepatitis C Virus - HIV Infections Location: Newport Beach, CA
- Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90024
Conditions: HIV - Hepatitis C - Infections Location: Los Angeles, CA
- Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90028
Conditions: HIV - Hepatitis C - Infections Location: Los Angeles, CA
- Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-90073
Conditions: HIV - Hepatitis C - Infections Location: Los Angeles, CA
- Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy - NCT00747539-93534
Conditions: HIV - Hepatitis C - Infections Location: Lancaster, CA
- Brief Intervention for Drug Misuse in the Emergency Department - NCT01124591-02903
Conditions: Substance Abuse Detection - HIV - Hepatitis B - Hepatitis C - Brief Intervention - HIV Infections Location: Providence, RI
- Cell Bound Complement Activation Proteins as Markers of Liver Injury - NCT01025531-15213
Conditions: Hepatitis C Location: Pittsburgh, PA
- Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects - NCT00136214-02215
Conditions: Hepatitis C Location: Boston, MA
- Characterization of Clonal B Cell Populations in HCV Infection - NCT00435201-10065
Conditions: Hepatitis C Location: New York, NY
- Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-06520
Conditions: Hepatitis C - Thrombocytopaenia Location: New Haven, CT
- Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-37212
Conditions: Hepatitis C - Thrombocytopaenia Location: Nashville, TN
- Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-96817
Conditions: Hepatitis C - Thrombocytopaenia Location: Honolulu, HI
- Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention - NCT01142882-10461
Conditions: HIV Infections - Hepatitis - Sexually Transmitted Infections Location: Bronx, NY
- Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention - NCT01142882-11217
Conditions: HIV Infections - Hepatitis - Sexually Transmitted Infections Location: Brooklyn, NY
- Computer-Assisted Tailored Cue-card Health [CATCH] Study - NCT01170741-27601
Conditions: Human Immunodeficiency Virus - STDs - Hepatitis, Viral, Human Location: Raleigh, NC
- Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection - NCT01097395-80045
Conditions: Hepatitis C Virus Location: Aurora, CO
- Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children - NCT00677183-53226
Conditions: Non-Alcoholic Steatohepatitis Location: Milwaukee, WI
- Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH) - NCT01154985-45242
Conditions: Steatohepatitis Location: Cincinnati, OH
- Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment - NCT01052701-21287
Conditions: Hepatitis C Location: Baltimore, MD
- Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity - NCT00878592-15213
Conditions: Post Liver Transplantation Weight Gain - Post Liver Transplantation Obesity - Nonalcoholic Steatohepatitis Location: Pittsburgh, PA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-01107
Conditions: Hepatitis B Infection Location: Springfield, MA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-02115
Conditions: Hepatitis B Infection Location: Boston, MA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-02905
Conditions: Hepatitis B Infection Location: Providence, RI
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10003
Conditions: Hepatitis B Infection Location: New York, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10010
Conditions: Hepatitis B Infection Location: New York, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10701
Conditions: Hepatitis B Infection Location: Yonkers, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-19141
Conditions: Hepatitis B Infection Location: Philadelphia, PA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-20037
Conditions: Hepatitis B Infection Location: Washington, DC
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-20740
Conditions: Hepatitis B Infection Location: College Park, MD
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-23249
Conditions: Hepatitis B Infection Location: Richmond, VA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-33136
Conditions: Hepatitis B Infection Location: Miami, FL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-33144
Conditions: Hepatitis B Infection Location: Miami, FL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-36116
Conditions: Hepatitis B Infection Location: Montgomery, AL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-60637
Conditions: Hepatitis B Infection Location: Chicago, IL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-78215
Conditions: Hepatitis B Infection Location: San Antonio, TX
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-85724
Conditions: Hepatitis B Infection Location: Tucson, AZ
- Effective Treatment of Hepatitis C in Substance Users - NCT00633243-06519
Conditions: Hepatitis C - Opiate Dependence Location: New Haven, CT
- Effects of HIV and Hepatitis C Virus on the Brain - NCT00494936-10029
Conditions: HIV Infections - Hepatitis C Location: New York, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-10016
Conditions: Acute On Chronic Hepatitis Location: New York, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-10032
Conditions: Acute On Chronic Hepatitis Location: New York, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-14642
Conditions: Acute On Chronic Hepatitis Location: Rochester, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-19140
Conditions: Acute On Chronic Hepatitis Location: Philadelphia, PA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-22908
Conditions: Acute On Chronic Hepatitis Location: Charlottesville, VA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-45267
Conditions: Acute On Chronic Hepatitis Location: Cincinnati, OH
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-46202
Conditions: Acute On Chronic Hepatitis Location: Indianapolis, IN
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-48109
Conditions: Acute On Chronic Hepatitis Location: Ann Arbor, MI
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-60637
Conditions: Acute On Chronic Hepatitis Location: Chicago, IL
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-71103
Conditions: Acute On Chronic Hepatitis Location: Shreveport, LA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-90048
Conditions: Acute On Chronic Hepatitis Location: Los Angeles, CA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis - NCT00973817-94115
Conditions: Acute On Chronic Hepatitis Location: San Francisco, CA
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-10021
Conditions: Chronic Hepatitis C Virus Infection Location: New York, NY
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-11030
Conditions: Chronic Hepatitis C Virus Infection Location: Manhasset, NY
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-21093
Conditions: Chronic Hepatitis C Virus Infection Location: Lutherville, MD
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-22031
Conditions: Chronic Hepatitis C Virus Infection Location: Fairfax, VA
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-27710
Conditions: Chronic Hepatitis C Virus Infection Location: Durham, NC
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-28207
Conditions: Chronic Hepatitis C Virus Infection Location: Charlotte, NC
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-28677
Conditions: Chronic Hepatitis C Virus Infection Location: Statesville, NC
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-30308
Conditions: Chronic Hepatitis C Virus Infection Location: Atlanta, GA
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-32610
Conditions: Chronic Hepatitis C Virus Infection Location: Gainesville, FL
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-48202
Conditions: Chronic Hepatitis C Virus Infection Location: Detroit, MI
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|